Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Quinn

Showing results (31-40 of 255) with videos related to

Pageof 26
Sort By:
Expert Review of Clinical Pharmacology|December 7, 2013
Novel tyrosine kinase inhibitors for renal cell carcinomaTanya B Dorff, Sumanta K Pal, David I Quinn
The Lancet. Oncology|December 3, 2014
Chromoplexy and hypoxic microenvironment drives prostate cancerLeslie K Ballas, Brian R Hu, David I Quinn
Clinical Nuclear Medicine|September 6, 2011
FDG PET/CT demonstration of pancreatic metastasis from prostate cancerBhushan Desai, Wafaa Elatre, David I Quinn, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2005
Molecular markers of prostate cancer outcomeDavid I Quinn, Susan M Henshall, Robert L Sutherland
Clinical Advances in Hematology & Oncology : H&O|March 13, 2012
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancerAndrew J Armstrong, Anna C Ferrari, David I Quinn
The Medical Journal of Australia|August 7, 1995
Non-steroidal anti-inflammatory drugsA G Johnson, D I Quinn, R O Day
Oncology (Williston Park, N.Y.)|August 20, 2014
Salvage chemotherapy for refractory germ cell tumorsTanya B Dorff, James S Hu, David I Quinn
Oncotargets and Therapy|October 8, 2016
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionSteven S Yu, David I Quinn, Tanya B Dorff
The Urologic Clinics of North America|May 3, 2005
The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomyAna M Aparicio, Anthony B Elkhouiery, David I Quinn
Biologics : Targets & Therapy|June 22, 2013
Tivozanib in the treatment of renal cell carcinomaMehmet Hepgur, Sarmad Sadeghi, Tanya B Dorff, et al.
Pageof 26

Showing results (31-40 of 255) with videos related to

Sort By:
Pageof 26
Expert Review of Clinical Pharmacology|December 7, 2013
Novel tyrosine kinase inhibitors for renal cell carcinomaTanya B Dorff, Sumanta K Pal, David I Quinn
The Lancet. Oncology|December 3, 2014
Chromoplexy and hypoxic microenvironment drives prostate cancerLeslie K Ballas, Brian R Hu, David I Quinn
Clinical Nuclear Medicine|September 6, 2011
FDG PET/CT demonstration of pancreatic metastasis from prostate cancerBhushan Desai, Wafaa Elatre, David I Quinn, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2005
Molecular markers of prostate cancer outcomeDavid I Quinn, Susan M Henshall, Robert L Sutherland
Clinical Advances in Hematology & Oncology : H&O|March 13, 2012
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancerAndrew J Armstrong, Anna C Ferrari, David I Quinn
The Medical Journal of Australia|August 7, 1995
Non-steroidal anti-inflammatory drugsA G Johnson, D I Quinn, R O Day
Oncology (Williston Park, N.Y.)|August 20, 2014
Salvage chemotherapy for refractory germ cell tumorsTanya B Dorff, James S Hu, David I Quinn
Oncotargets and Therapy|October 8, 2016
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionSteven S Yu, David I Quinn, Tanya B Dorff
The Urologic Clinics of North America|May 3, 2005
The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomyAna M Aparicio, Anthony B Elkhouiery, David I Quinn
Biologics : Targets & Therapy|June 22, 2013
Tivozanib in the treatment of renal cell carcinomaMehmet Hepgur, Sarmad Sadeghi, Tanya B Dorff, et al.
Pageof 26